$764.99 Million in Sales Expected for Endo International plc – (ENDP) This Quarter

Brokerages predict that Endo International plc – (NASDAQ:ENDP) (TSE:ENL) will post sales of $764.99 million for the current quarter, according to Zacks. Six analysts have made estimates for Endo International’s earnings, with estimates ranging from $750.26 million to $779.46 million. Endo International posted sales of $1.24 billion during the same quarter last year, which would indicate a negative year over year growth rate of 38.3%. The company is expected to report its next earnings report on Tuesday, February 27th.

On average, analysts expect that Endo International will report full year sales of $764.99 million for the current financial year, with estimates ranging from $3.45 billion to $3.51 billion. For the next financial year, analysts expect that the business will report sales of $3.07 billion per share, with estimates ranging from $2.89 billion to $3.20 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. During the same quarter in the previous year, the company posted $1.01 earnings per share. The business’s quarterly revenue was down 11.0% compared to the same quarter last year.

A number of brokerages have commented on ENDP. Cantor Fitzgerald set a $7.00 target price on Endo International and gave the company a “hold” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. ValuEngine upgraded Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BidaskClub downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, Citigroup decreased their price target on Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $10.79.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diamond Hill Capital Management Inc. boosted its stake in shares of Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after acquiring an additional 228,426 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Endo International by 18.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock worth $4,447,000 after purchasing an additional 62,822 shares during the last quarter. Nationwide Fund Advisors lifted its position in shares of Endo International by 4.9% during the 2nd quarter. Nationwide Fund Advisors now owns 360,787 shares of the company’s stock worth $4,030,000 after purchasing an additional 16,913 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Endo International by 4.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock worth $6,497,000 after purchasing an additional 27,414 shares during the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Endo International during the 3rd quarter worth about $293,000. Institutional investors own 93.06% of the company’s stock.

Endo International (NASDAQ ENDP) opened at $7.11 on Friday. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. Endo International has a 52 week low of $5.77 and a 52 week high of $14.45. The company has a market capitalization of $1,587.76, a PE ratio of 1.47, a price-to-earnings-growth ratio of 2.47 and a beta of 0.59.

ILLEGAL ACTIVITY WARNING: “$764.99 Million in Sales Expected for Endo International plc – (ENDP) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/21/764-99-million-in-sales-expected-for-endo-international-plc-endp-this-quarter.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply